For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ8571Fa&default-theme=true
RNS Number : 8571F Dr. Martens PLC 26 September 2024
Dr. Martens plc
Notification of transaction by Person Closely Associated with a PDMR
Dr. Martens plc (the ‘Company’) announces that on 26 September 2024 the
following transaction in the Company’s ordinary shares was undertaken by a
person closely associated with a director / person discharging managerial
responsibility (‘PDMR’).
The notification set out below is provided in accordance with the requirements
of Article 19 of the UK Market Abuse Regulation.
1. Details of PDMR / person closely associated with them
a) Name Katie Wilson
2. Reasons for the notification
a) Position / status Person Closely Associated with Giles Wilson,
Chief Financial Officer and PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Full name of the entity Dr. Martens plc
b) Legal Entity Identifier code 213800QPT8YM6NQZPH28
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place
where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of GBP 0.01 each
Identification Code ISIN: GB00BL6NGV24
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
£0.554 30,000
d) Aggregated information
Aggregated volume N/A – single transaction
Price
e) Date of the transaction 26 September 2024
f) Place of the transaction London Stock Exchange (XLON)
d)
Aggregated information
Aggregated volume
Price
N/A – single transaction
e)
Date of the transaction
26 September 2024
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUNVURSBUKUAR